Main Industry
Biotechnology
Main Product/Service
Acepodia’s core offering is allogeneic cell‑therapy for cancer — using targeted design and cell‑engineering technologies to develop safe and effective therapeutic cell drugs, aiming to provide patients with a next‑generation, broadly applicable cancer tre
Founded Year
2023
Unified Business No.
82983710
Status
Active
Number of Employees
60
Total Paid-in
Capital
0 (NT$)
Location of Company
Taiwan
, Taipei City
Exit Status
Emerging Stock Exchange(2023)
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person. Please do not contact this platform for company inquiries.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Acepodia Inc., a member (No. 64) of the Taiwan Research‑based Biopharmaceutical Manufacturers Association (TRPMA), is a biotech startup focused on developing novel allogeneic cell therapies for cancer, aiming to advance new possibilities in oncology treatment.
